Mitemcinal (GM-611), an orally active motilin agonist, facilitates defecation in rabbits and dogs without causing...

Area of Science:

• Gastroenterology
• Pharmacology
• Preclinical Research

Background:

• Constipation is a common gastrointestinal disorder requiring effective treatment options.
• Motilin agonists represent a potential therapeutic class for managing bowel motility.
• Current treatments like sennoside can cause undesirable side effects such as loose stools.

Purpose of the Study:

• To investigate the pro-defecation effects of mitemcinal (GM-611), an orally active motilin agonist.
• To compare the efficacy and side effect profile of mitemcinal with sennoside in animal models.
• To evaluate mitemcinal's potential as a novel therapeutic agent for constipation.

Main Methods:

• Oral administration of mitemcinal and sennoside to normal rabbits and dogs.
• Induction of constipation in rabbits using morphine.
• Dose-dependent evaluation of stool weight, stool water content, and time to first bowel movement.

Main Results:

• Mitemcinal increased stool weight dose-dependently in normal rabbits without causing loose stools.
• In morphine-induced constipation, mitemcinal significantly increased stool weight, restoring it to 83.9% of control levels without altering water content.
• Mitemcinal reduced the time to first bowel movement in dogs without inducing diarrhea.

Conclusions:

• Mitemcinal effectively facilitates defecation in preclinical models without inducing severe diarrhea.
• Mitemcinal demonstrates a favorable profile compared to sennoside, with early onset and short duration of action.
• Mitemcinal shows potential as a novel therapeutic agent for constipation, offering better control over defecation timing.